Targeting Sphingosine Kinase 2 (SphK2) by ABC294640 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2015 Sep 5

PMID 26337959

Citations 50

Authors

Cai Xun

Min-Bin Chen

Li Qi

Zhang Tie-Ning

Xue Peng

Li Ning

Chen Zhi-Xiao

Wang Li-Wei

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC) is a major health problem in China and around the world. It is one of the leading causes of cancer-related deaths. Research groups are thus searching for novel and more efficient anti-CRC agents.

Results: Here we demonstrated that ABC294640, a novel SphK2 inhibitor, induced growth inhibition and apoptosis in transformed and primary CRC cells. The SphK activity was remarkably inhibited by ABC294640, accompanied by sphingosine-1-phosphate (S1P) depletion and ceramide incensement in CRC cells. Exogenously-added S1P inhibited ABC294640-induced HT-29 cell lethality. While C6 ceramide and SphK1 inhibitor SKI-II facilitated ABC294640-induced cytotoxicity against HT-29 cells. ABC294640 inhibited AKT-S6K1, but activated JNK signaling in transformed and primary CRC cells. JNK inhibitors (SP600125 and JNKi-II) alleviated ABC294640-induced CRC cell apoptosis. Moreover, a low concentration of ABC294640 sensitized the activity of 5-FU and cisplatin in vitro. In vivo, ABC294640 oral administration dramatically inhibited HT-29 xenografts growth in nude mice.

Conclusions: Targeting of SphK2 by ABC294640 potently inhibits CRC cell growth both in vitro and in vivo, ABC294640 could be developed as a novel therapeutic for the treatment of CRC.

Citing Articles

Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition.

Janakiraman H, Gao Z, Zhu Y, Dong J, Becker S, Janneh A World J Oncol. 2024; 15(5):744-757.

PMID: 39328328 PMC: 11424120. DOI: 10.14740/wjon1890.

5-Fluorouracil resistance due to sphingosine kinase 2 overexpression in colorectal cancer is associated with myeloid-derived suppressor cell-mediated immunosuppressive effects.

Li X, Chen Y, Liang Y, Shi W BMC Cancer. 2024; 24(1):983.

PMID: 39118083 PMC: 11313101. DOI: 10.1186/s12885-024-12742-4.

Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.

Maines L, Keller S, Smith R, Schrecengost R, Smith C Cancers (Basel). 2024; 16(9).

PMID: 38730731 PMC: 11082966. DOI: 10.3390/cancers16091779.

Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.

Asumda F, Campbell N, Hassan M, Fathi R, Vasquez Rico D, Kiem M Cancers (Basel). 2024; 16(5).

PMID: 38473407 PMC: 10930726. DOI: 10.3390/cancers16051050.

Developing new ceramide analogs against non-small cell lung cancer (NSCLC).

Dai L, Goyal N, Liu J, Foroozesh M, Qin Z Am J Cancer Res. 2024; 14(1):86-96.

PMID: 38323290 PMC: 10839310.

References

Li C, Cui J, Chen M, Liu C, Liu F, Zhang Q . The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. Cancer Biol Ther. 2015; 16(1):34-42. PMC: 4623257. DOI: 10.4161/15384047.2014.972274. View

Gandy K, Obeid L . Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta. 2012; 1831(1):157-66. PMC: 3661866. DOI: 10.1016/j.bbalip.2012.07.002. View

Gangoiti P, Granado M, Alonso A, Goni F, Gomez-Munoz A . Implication of ceramide, ceramide 1-phosphate and sphingosine 1-phosphate in tumorigenesis. Transl Oncogenomics. 2011; 3:81-98. PMC: 3022355. View

Gong L, Yang B, Xu M, Cheng B, Tang X, Zheng P . Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol. 2013; 73(1):69-77. DOI: 10.1007/s00280-013-2318-3. View

Kohama T, Olivera A, Edsall L, Nagiec M, Dickson R, Spiegel S . Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem. 1998; 273(37):23722-8. DOI: 10.1074/jbc.273.37.23722. View

French K, Zhuang Y, Maines L, Gao P, Wang W, Beljanski V . Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010; 333(1):129-39. PMC: 2846016. DOI: 10.1124/jpet.109.163444. View

Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z . Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(2):e90362. PMC: 3937388. DOI: 10.1371/journal.pone.0090362. View

Chen C, Lin C, Chang W, Huang W, Teng C, Lin Y . Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood. 2008; 111(8):4365-74. DOI: 10.1182/blood-2007-08-106336. View

Altura B, Shah N, Shah G, Zhang A, Li W, Zheng T . Short-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review. Int J Clin Exp Med. 2014; 7(1):1-21. PMC: 3902236. View

10.

Maceyka M, Payne S, Milstien S, Spiegel S . Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2003; 1585(2-3):193-201. DOI: 10.1016/s1388-1981(02)00341-4. View

11.

Palta M, Czito B, Willett C . Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. Nat Rev Clin Oncol. 2014; 11(4):182-4. DOI: 10.1038/nrclinonc.2014.43. View

12.

Gao P, Peterson Y, Smith R, Smith C . Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One. 2012; 7(9):e44543. PMC: 3438171. DOI: 10.1371/journal.pone.0044543. View

13.

Nuvoli B, Santoro R, Catalani S, Battistelli S, Benedetti S, Canestrari F . CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin Cancer Res. 2014; 33:24. PMC: 3975718. DOI: 10.1186/1756-9966-33-24. View

14.

Schmoll H, Stein A . Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol. 2014; 11(2):79-80. DOI: 10.1038/nrclinonc.2013.254. View

15.

Dimanche-Boitrel M, Rebillard A, Gulbins E . Ceramide in chemotherapy of tumors. Recent Pat Anticancer Drug Discov. 2011; 6(3):284-93. DOI: 10.2174/157489211796957838. View

16.

Easton J, Houghton P . mTOR and cancer therapy. Oncogene. 2006; 25(48):6436-46. DOI: 10.1038/sj.onc.1209886. View

17.

Ogretmen B, Hannun Y . Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004; 4(8):604-16. DOI: 10.1038/nrc1411. View

18.

Yang J, Yang C, Zhang S, Mei Z, Shi M, Sun S . ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther. 2015; 16(8):1194-204. PMC: 4623419. DOI: 10.1080/15384047.2015.1056944. View

19.

Yang K, Jiang L, Hu Y, Yu J, Chen H, Yao Y . Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation. J Exp Clin Cancer Res. 2015; 34:40. PMC: 4427949. DOI: 10.1186/s13046-015-0158-1. View

20.

Pyne S, Bittman R, Pyne N . Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. Cancer Res. 2011; 71(21):6576-82. PMC: 3206172. DOI: 10.1158/0008-5472.CAN-11-2364. View